Is Bevacizumab Better Than Photodynamic Therapy for Myopic Subretinal Neovascularization?

September 21, 2009

Yet another nail in the coffin for laser for macular disease. A study in AJO this month demonstrated superior results for Bevacizumab compared to photodynamic therapy¬†(PDT) for myopic subretinal neovascularization (SRN). It would seem a few years from now, we will look at laser treatment for the macula like we look at blood-letting. Oh well- it’s great progress!

 

 



Comments

Jump down to form below to submit your own comments

Trackback URL
http://eyedocnews.com/002199-bevacizumab-better-than-pdt-for-myopic-choroidal-neovascularization/trackback/

Have insights to contribute? Please submit your comment below